Zhang, H., Yu, P., Tomar, V. S., Chen, X., Atherton, M. J., Lu, Z., Zhang, H. G., Li, S., Ortiz, A., Gui, J., Leu, N. A., Yan, F., Blanco, A., Meyer-Ficca, M. L., Meyer, R. G., Beiting, D. P., Li, J., Nunez-Cruz, S., O'Connor, R. S., Johnson, L. R., Minn, A. J., George, S. S., Koumenis, C., Diehl, J. A., Milone, M. C., Zheng, H., Fuchs, S. Y. Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors Nat Cancer 3: 808-820, 2022.Gedney, A., Salah, P., Mahoney, J. A., Krick, E., Martins, R., Scavello, H., Lenz, J. A., Atherton, M. J. Evaluation of the anti-tumour activity of Coriolus versicolor polysaccharopeptide (I''m-Yunity) alone or in combination with doxorubicin for canine splenic hemangiosarcoma Veterinary and Comparative Oncology 20: 688-696, 2022.Atherton, M. J., Rotolo, A., Haran, K. P., Mason, N. J. Case report: clinical and serological hallmarks of cytokine release syndrome in a canine B cell lymphoma patient treated with autologous CAR-T cells Front Vet Sci 9: 824982, 2022.Atherton, M. J., Mason, N. J. Bite-size introduction to canine hematologic malignancies Blood Adv 6: 4073-4084, 2022.Rotolo, A., Atherton, M. J., Kasper, B. T., Haran, K. P., Mason, N. J. Genetic re-direction of canine primary T cells for clinical trial use in pet dogs with spontaneous cancer STAR Protoc 2: 100905, 2021.Lenz, J. A., Assenmacher, C. A., Costa, V., Louka, K., Rau, S., Keuler, N. S., Zhang, P. J., Maki, R. G., Durham, A. C., Radaelli, E., Atherton, M. J. Increased tumor-infiltrating lymphocyte density is associated with favorable outcomes in a comparative study of canine histiocytic sarcoma Cancer Immunology, Immunotherapy : , 2021.LeBlanc, A. K., Atherton, M., Bentley, R. T., Boudreau, C. E., Burton, J. H., Curran, K. M., Dow, S., Giuffrida, M. A., Kellihan, H. B., Mason, N. J., Oblak, M., Selmic, L. E., Selting, K. A., Singh, A., Tjostheim, S., Vail, D. M., Weishaar, K. M., Berger, E. P., Rossmeisl, J. H., Mazcko, C. Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE v2) following investigational therapy in dogs and cats Veterinary and Comparative Oncology 19: 311-352, 2021.Benjamin, S. E., Sorenmo, K. U., Krick, E. L., Salah, P., Walsh, K. A., Weinstein, N. M., Keuler, N. S., Avery, A. C., Atherton, M. J., Lenz, J. A. Response-based modification of CHOP chemotherapy for canine B-cell lymphoma Veterinary and Comparative Oncology 19: 541-550, 2021.Pol, J. G., Atherton, M. J., Stephenson, K. B., Bridle, B. W., Workenhe, S. T., Kazdhan, N., McGray, A. R., Wan, Y., Kroemer, G., Lichty, B. D. Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning J Immunother Cancer 8: , 2020.Panjwani, M. K., Atherton, M. J., MaloneyHuss, M. A., Haran, K. P., Xiong, A., Gupta, M., Kulikovsaya, I., Lacey, S. F., Mason, N. J. Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma Oncoimmunology 9: 1676615, 2020.Atherton, M. J., Lenz, J. A., Mason, N. J. Sarcomas-A barren immunological wasteland or field of opportunity for immunotherapy? Veterinary and Comparative Oncology 18: 447-470, 2020.Pol, J. G., Acuna, S. A., Yadollahi, B., Tang, N., Stephenson, K. B., Atherton, M. J., Hanwell, D., El-Warrak, A., Goldstein, A., Moloo, B., Turner, P. V., Lopez, R., LaFrance, S., Evelegh, C., Denisova, G., Parsons, R., Millar, J., Stoll, G., Martin, C. G., Pomoransky, J., Breitbach, C. J., Bramson, J. L., Bell, J. C., Wan, Y., Stojdl, D. F., Lichty, B. D., McCart, J. A. Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials Oncoimmunology 8: e1512329, 2019.Pol, J. G., Atherton, M. J., Bridle, B. W., Stephenson, K. B., Le Boeuf, F., Hummel, J. L., Martin, C. G., Pomoransky, J., Breitbach, C. J., Diallo, J. S., Stojdl, D. F., Bell, J. C., Wan, Y., Lichty, B. D. Development and applications of oncolytic Maraba virus vaccines Oncolytic Virother 7: 117-128, 2018.Atherton, M. J., Stephenson, K. B., Tzelepis, F., Bakhshinyan, D., Nikota, J. K., Son, H. H., Jirovec, A., Lefebvre, C., Dvorkin-Gheva, A., Ashkar, A. A., Wan, Y., Stojdl, D. F., Belanger, E. C., Breau, R. H., Bell, J. C., Saad, F., Singh, S. K., Diallo, J. S., Lichty, B. D. Transforming the prostatic tumor microenvironment with oncolytic virotherapy Oncoimmunology 7: e1445459, 2018.Atherton, M. J., Stephenson, K. B., Nikota, J. K., Hu, Q. N., Nguyen, A., Wan, Y., Lichty, B. D. Preclinical development of peptide vaccination combined with oncolytic MG1-E6E7 for HPV-associated cancer Vaccine 36: 2181-2192, 2018.